



## CLAIMS

1. Use of a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a compound of Formula I:




or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a PI3K related disease or disorder in a subject in need thereof, wherein R is hydrogen or an acyl group.

2. The use of claim 1, wherein said PI3K related disease or disorder is a cell proliferative disorder.
3. The use of claim 2 wherein the cell proliferative disorder is a cancer.
4. The use of claim 3, wherein the cancer is selected from the group consisting of papilloma, blastoglioma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.
5. Use of a pharmaceutical composition comprising as an active ingredient a compound of Formula I:




and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of an HDAC-mediated disease.

6. Use of a pharmaceutical composition comprising as an active ingredient a compound of Formula I:



and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of both PI3K and HDAC mediated diseases.

7. Use of a therapeutically effective amount of the pharmaceutical composition comprising as an active ingredient a compound represented by the formula




or a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of a PI3K related disease or disorder in a subject in need thereof.

8. The use of claim 5 wherein said PI3K related disease or disorder is a cell proliferative disorder.
9. The use of claim 8 wherein the cell proliferative disorder is a cancer.
10. The use of claim 9 wherein the cancer is selected from the group consisting of papilloma, blastoglioma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer,


bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.

11. Use of a pharmaceutical composition comprising as an active ingredient a compound represented by the formula



or a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of an HDAC-mediated disease.

12. Use of a pharmaceutical composition comprising as an active ingredient a compound represented by the formula



or a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of both PI3K and HDAC mediated diseases.